| | 机构专用 | | 1486次 43.27% | 763.32 | 0.70% | | --- | --- | --- | --- | --- | --- | | 2 | 机构专用 | | 1486次 43.27% | 1223.45 | 1.12% | | 3 | 国金证券股份有限公司深圳分公司 | | 299次 41.47% | 91.39 | 0.08% | | | 机构专用 | | 1486次 43.27% | 95.16 | 0.09% | | 5 | 机构专用 | | 1486次 43.27% | 0.00 | 0.00% | | | | (买入前5名与卖出前5名)总合计: | | 7871.85 | 7.20% | | 买入金额最大的前5名 | | | | | | | --- | --- | --- | --- | --- | --- | | 序号 | 交易营业部名称 | | | 买入金额(万) | 占总成交比例 | | 1 | 中信证券股份有限公司杭州凤起路证券营业部 | 40次 30.00% | 0 | 1643.46 | 1.50% | | 2 | 国信证券股份有限公司浙江互联网分公 ...

深交所公开信息显示，当日该股因日跌幅偏离值达-10.23%上榜，机构专用席位净卖出1.16亿元。 昂利康今日下跌9.46%，全天换手率9.90%，成交额10.94亿元，振幅7.50%。龙虎榜数据显示，机构净卖 出1.16亿元，营业部席位合计净买入1061.60万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交2.63亿元，其中，买入成交额为7871.85 万元，卖出成交额为1.84亿元，合计净卖出1.05亿元。 具体来看，今日上榜的营业部中，共有4家机构专用席位现身，即买四、卖一、卖二、卖四、卖五，合 计买入金额2081.92万元，卖出金额1.37亿元，合计净卖出1.16亿元。 近半年该股累计上榜龙虎榜12次，上榜次日股价平均涨2.61%，上榜后5日平均涨3.74%。 昂利康8月5日交易公开信息 | 买/ 卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 中信证券股份有限公司杭州凤起路证券营业部 | 1643.46 | 1.17 | | 买二 | 国信证券股份有限公司浙江互联网分公司 | 1526.36 | ...

Group 1 - The Helicobacter pylori concept sector declined by 0.50%, ranking among the top declines in concept sectors, with notable declines in stocks such as Keta Bio, Anglikang, and Asia-Pacific Pharmaceutical [1][2] - Among the 49 stocks in the Helicobacter pylori concept sector, 27 stocks saw price increases, with Zhongheng Group, Hanyu Pharmaceutical, and *ST Sansheng leading the gains at 9.85%, 5.63%, and 5.05% respectively [1][4] - The Helicobacter pylori concept sector experienced a net outflow of 1.725 billion yuan in main funds, with Hanyu Pharmaceutical seeing the largest outflow of 909.33 million yuan [2][3] Group 2 - The top gainers in the concept sectors included the Armament Reorganization concept at 6.12%, PEEK materials at 4.11%, and Brain-Computer Interface at 2.72% [2] - The main funds saw inflows in stocks such as Zhongheng Group, Baicheng Pharmaceutical, and Asia Treasure Pharmaceutical, with inflows of 88.23 million yuan, 63.86 million yuan, and 19.51 million yuan respectively [2][4] - The stocks with the largest net outflows in the Helicobacter pylori concept included Asia-Pacific Pharmaceutical at -8.16%, Keta Bio at -10.28%, and Anglikang at -9.46% [2][3]

Market Overview - A-shares regained the 3600-point mark, with the Shanghai Composite Index rising by 0.53% to 3602.13 points, while the Shenzhen Component increased by 0.14% and the ChiNext Index fell by 0.26% [1][2] Trading Volume - The trading volume in the Shanghai and Shenzhen markets exceeded 1 trillion yuan, reaching 10057 billion yuan, an increase of 849 billion yuan compared to the previous trading day [2] Sector Performance - The military industry sector saw significant activity, with several stocks hitting the daily limit. The PEEK materials sector experienced a surge, and the gaming sector has risen for three consecutive days [2][4][7] Military Sector Highlights - Notable stocks in the military sector included Aerospace Intelligent Equipment, which hit a 20% limit up, and Great Wall Military Industry, which also reached a 10% limit up. The cumulative increase for Great Wall Military Industry since June 18, 2025, is 181.58% [4][5] - The military sector is supported by a continuous increase in global military spending, with China's military manufacturing competitive advantage being underestimated [6] Gaming Sector Highlights - The gaming sector is experiencing a new growth wave, driven by AI technology and the summer season. Stocks like Perfect World and Giant Network saw significant increases [7][8] PEEK Materials Sector - The PEEK materials sector saw a rise, with Huami New Materials on the Beijing Stock Exchange increasing by over 20%. Other companies like Xinhan New Materials and Zhongxin Fluorine Materials also hit the daily limit [9] Steel Sector Performance - The steel sector continued to strengthen, with Maanshan Iron & Steel hitting a 10% limit up. Other companies like Baotou Steel and Fangda Special Steel also saw gains [9][10] Pharmaceutical Sector - The innovative drug sector experienced a pullback after a previous surge, with several stocks in traditional Chinese medicine showing significant declines [11]

Market Performance - The three major A-share indices showed mixed results, with the Shanghai Composite Index up by 0.53%, the Shenzhen Component Index up by 0.14%, and the ChiNext Index down by 0.26% [2] - The North China 50 Index increased by 0.18%, and the total trading volume in the Shanghai and Shenzhen markets reached 101.86 billion yuan, an increase of 8.6 billion yuan compared to the previous day [2] - Over 3,300 stocks in the market experienced gains [2] Sector Performance - The PEEK materials sector, military equipment restructuring, and photolithography machine sectors saw significant gains, while the pharmaceutical sector underwent adjustments [2] - PEEK materials showed strong performance across the board, with Zhongxin Fluorine Materials hitting the daily limit, and companies like Xinhan New Materials, Huami New Materials, and Nanjing Julong rising over 10% [2] - The military equipment restructuring concept experienced fluctuations, with Great Wall Military Industry reaching the daily limit [2] - The photolithography machine sector also performed well, with Zhangjiang Hi-Tech hitting the daily limit [2] - The pharmaceutical sector faced collective adjustments, with Qizheng Tibetan Medicine hitting the daily limit down, and companies like Anglikang and Nanjing New Medicine dropping over 9% [2]

Group 1 - The stock of Aonlikang is approaching a limit down, indicating significant selling pressure [1] - Several pharmaceutical companies, including Nanjing New Pharmaceutical, Huason Pharmaceutical, Yuekang Pharmaceutical, Chenxin Pharmaceutical, Guizhou Bailing, and Shutaishen, have all experienced declines exceeding 6% [1]

Group 1 - Gao Ling Information announced that three shareholders plan to reduce their holdings by a total of up to 2.42% of the company's shares due to personal funding needs [1] - The shareholders include Zhuhai Hengqin New Area Zixiao Investment Partnership, Zhuhai Hengqin New Area Qucheng Investment Partnership, and Zhuhai Huajin Lingyue Intelligent Manufacturing Industry Investment Fund [1] - Gao Ling Information specializes in the R&D, production, and sales of telecommunications network communication equipment, environmental IoT application products, and network and information security products [1] Group 2 - Anglikang has only one innovative drug project under research, ALK-N001, which is currently in Phase I clinical trials [2] - The company is also considering a new innovative drug pipeline project, ALK-N002, which is still in the candidate selection phase [2] - Anglikang focuses on the production and manufacturing of pharmaceuticals, including chemical raw materials and preparations [2] Group 3 - Qixiang Tengda announced the completion of maintenance and technical upgrades for its 300,000 tons/year propylene oxide facility, which has resumed normal production [3] - The company operates in the chemical manufacturing and supply chain management sectors [3] Group 4 - Delisi signed a strategic cooperation agreement with Xiamen Haifusheng Food Group and Xin Sanhe Food Co., Ltd. to collaborate in product supply, market expansion, and technology [4] - Delisi specializes in the production and sales of frozen meat and related products [4] Group 5 - Jinlang Technology's application for issuing convertible bonds has been approved by the Shenzhen Stock Exchange [5] - The company is engaged in the R&D, production, and sales of string inverters [5] Group 6 - Lingyi Zhi Zao plans to acquire a 66.46% stake in Jiangsu Keda through a combination of issuing convertible bonds and cash [6] - The company provides comprehensive intelligent manufacturing services and solutions [6] Group 7 - Jinshi Technology intends to publicly transfer 100% equity of its wholly-owned subsidiary, Hunan Jinshi Technology [7] - The company focuses on digital sanitation, water ecology, and solid waste disposal [7] Group 8 - Qidi Environment announced that 2 million shares held by shareholder Sander Group have been transferred through judicial auction [8] - The company operates in the environmental management sector [8] Group 9 - Guang'an Aizhong expects a reduction in net profit of approximately 39.38 million due to the implementation of a low valley electricity price policy [9] - The company is involved in power generation, supply, and natural gas supply [9] Group 10 - Kangyuan Pharmaceutical received a drug registration certificate for its proprietary product, Canpu Granules, used for treating chronic pelvic pain [10] - The company specializes in the R&D, production, and sales of pharmaceuticals [10] Group 11 - Changqing Technology announced that two shareholders plan to reduce their holdings by up to 5.98% due to personal funding needs [11] - The company focuses on rail transit and building decoration businesses [11] Group 12 - Huaren Pharmaceutical's shareholder plans to reduce its holdings by up to 1% of the company's total shares [12] - The company is a state-controlled pharmaceutical health industry group [12] Group 13 - Jinkai New Energy announced the completion of the first phase of an AI computing power technology service contract [13] - The company is involved in the development, investment, construction, and operation of renewable energy power [13] Group 14 - Sany Heavy Industry has repurchased a total of 72.6792 million shares, amounting to 1.355 billion [14] - The company specializes in the R&D, manufacturing, and sales of engineering machinery [14] Group 15 - Chip导科技 plans to acquire 100% of Shunlei Technology and 17.15% of Shunlei Technology through convertible bonds and cash [15] - The company focuses on the R&D and sales of power semiconductors [15] Group 16 - Tuo Shan Heavy Industry reported that its recent operating conditions are normal, with no significant changes in the internal and external business environment [16] - The company specializes in the R&D, design, production, and sales of engineering machinery components [16] Group 17 - Chang'an Automobile reported a July sales figure of 210,600 vehicles, a year-on-year increase of 23.43% [17] - The company is engaged in the R&D, manufacturing, and sales of vehicles and engines [17]

长江商报奔腾新闻记者 潘瑞冬 业绩承压，股价却大幅上涨，昂利康（002940.SZ）多次发布股票交易异常波动公告。 8月3日晚间，昂利康公告称，公司股票连续2个交易日(2025年7月31日、8月1日)收盘价格涨幅偏离值累 计超过20%，针对公司股票交易异常波动情况，公司董事会对有关事项进行了核查。 昂立康表示，公司不存在应披露而未披露的信息，公司前期披露的信息不存应在需要更正或补充披露的 事项。 不过，公司在公告中提及，公司关注到近期市场对创新药业务关注度较高。但昂利康称，公司目前在研 的创新药项目仅有一个，系ALK-N001项目，该项目于2025年4月获得药物临床试验批准通知书，截至 公告披露日，该项目尚处于I期临床试验阶段。 另外，公司关注到近期有投资者关心公司ALK-N002项目，该项目系公司于2025年年初计划新引入的创 新药管线项目，已列入年度募集资金投资项目实施内容的调整计划中。截至公告披露日，该项目有多个 候选药物在筛选和商榷中，尚未确定具体管线。公司还提醒投资者注意投资风险。 长江商报奔腾新闻记者注意到，6月以来，昂利康的股价涨幅巨大，6月至7月，公司股价从14.84元/股 涨至7月底收盘价的 ...

编辑 杨娟娟 新京报贝壳财经讯 8月3日，昂利康发布股票交易异常波动公告称，公司关注到近期市场对创新药业务 关注度较高。公司目前在研的创新药项目仅有一个，系ALK-N001项目，该项目于2025年4月获得药物 临床试验批准通知书，截至公告披露日，该项目尚处于I期临床试验阶段。另外，公司关注到近期有投 资者关心公司ALK-N002项目，该项目系公司于2025年年初计划新引入的创新药管线项目，已列入年度 募集资金投资项目实施内容的调整计划中，截至公告披露日，该项目有多个候选药物在筛选和商榷中， 尚未确定具体管线，由于候选药物的相关适应症涉及商业秘密，公司将依据项目进展情况严格按照相关 规定及时履行信息披露义务。 ...

000558 天府文旅 B004 000826 启迪环境 B001 000998 隆平高科 B001 001236 弘业期货 A07 001314 亿道信息 A06 001324 长青科技 A06 002037 保利联合 A06 002198 嘉应制药 A07 002219 新里程 B001 002330 得利斯 B007 002408 齐翔腾达 B003 002424 贵州百灵 A07 002600 领益智造 B007 002629 仁智股份 A07 002634 棒杰股份 A07 002716 湖南白银 A06 002775 文科股份 B004 002799 环球印务 A07 002921 联诚精密 A07 002940 昂利康 B004 002951 金时科技 A06 300691 联合光电 A06 301632 广东建科 A08 600009 上海机场 A08 600031 三一重工 A08 600104 上汽集团 A08 600166 福田汽车 B003 600507 方大特钢 B001 平安基金 B003 融通基金 B007 上银基金 B005 天弘基金 B006 太平基金 B005 信达证券基金 ...